Fulranumab
Fulranumab is a monoclonal antibody against nerve growth factor.[1] It was designed for the treatment of pain.[2]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | NGF |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6446H9930N1718O2018S50 |
| Molar mass | 145385.35 g·mol−1 |
  (what is this?) (verify) | |
Johnson & Johnson licensed the drug from Amgen in a deal valued at around US$425 million in 2008. In 2016 Johnson & Johnson discontinued all phase III trials of fulranumab and returned the rights to its originator. The company said the decision was based on "strategic portfolio prioritisation and was not based on any emerging safety concerns from the phase III clinical studies with fulranumab" in osteoarthritic pain.[3]
See also
References
- Monoclonal Antibodies Targeted Against Nerve Growth Factor For the Treatment of Chronic Pain, By Ken Verburg, PhD - Medicines Development Group, Pfizer Inc., Arthritis Advisory Committee Meeting, 12 March 2012
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Fulranumab" (PDF). American Medical Association.
- J&J drops NGF blocker fulranumab, Article by Phil Taylor, 4 April 2016, PMLiVE
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.